2026: Guest Chair Professor of BIOPIC, Peking University

2026: Visiting Professor, Macau University of Science and Technology

2025: Fellowships: Academia Europaea; Hungarian Academy of Sciences; Australian Academy of Technological Sciences and Engineering

2024: Honorary Doctor of Science, UTAR University

2015: Fellowship: Australian Academy of Health & Medical Sciences

1995: PhD, University of Melbourne, Walter and Eliza Hall Institute

1993: Fellowships: Royal Australasian College of Physicians (RACP) & Royal College of Pathologists of Australasia (RCPA)

1986: Bachelor of Medicine and Bachelor of Surgery, University of Sydney

Professional Experience

2018-2020: President, International Society for Cell & Gene Therapy

2008–2026: Chair, Gene Technology Technical Advisory Committee, Office of the Gene Technology Regulator

1999-2024: Founding Director & Head, Department of Cell & Molecular Therapies, Royal Prince Alfred Hospital

Board, Advisory & Consulting Roles (Pfizer, CSL Behring, Rarecyte, Cynata, Kennerton Capital, Woke Pharmaceuticals)

Professor John Rasko AO is a globally recognised leader in gene and cell therapy, regenerative medicine, and molecular biotechnology. As a clinical haematologist, pathologist and scientist, he has shaped the medical translation of advanced therapeutics in Australia and internationally. From 1999 to 2024, he directed the Department of Cell & Molecular Therapies at Royal Prince Alfred Hospital and the Gene & Stem Cell Therapy Program at the University of Sydney, building world-class programs bridging discovery and real-world impact.

Career Impact

Clinical trials development strategies (Phase I–III)
Gene & cell therapy
Translational & regenerative medicine
GMP manufacturing & quality oversight
Scientific communication & stakeholder engagement
Licensing, IP, and public-private partnerships
Regulatory & ethics leadership (GTTAC, WHO INN Committee, Biosafety & Ethics)